[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658060":3},{"organization":4,"outcomesModule":7,"designInfo":56,"detailedDescription":11,"studyPopulation":59,"armGroups":60,"interventions":82,"overallOfficials":88,"centralContacts":91,"locations":99,"responsibleParty":111,"collaborators":11,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":11,"enrollmentInfo":123,"targetDuration":11,"studyType":126,"phases":11,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":133,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":18,"otherOutcomes":11},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Number of participants in each study cohort",null,"Baseline and months 1, 2, 3, 6, 9, 12 and 15",{"measure":14,"description":11,"timeFrame":15},"Absolute change (mmHg) from baseline in resting peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography","Baseline and at months 1, 2, 3, 6, 9, 12 and 15",{"measure":17,"description":11,"timeFrame":15},"Absolute change (mmHg) from baseline in post-Valsalva peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography",[19,21,23,25,27,29,32,35,37,40,43,45,47,49,53],{"measure":20,"description":11,"timeFrame":15},"Number of participants with at least 1-class improvement from baseline in New York Heart Association (NYHA) functional class",{"measure":22,"description":11,"timeFrame":15},"New York Heart Association (NYHA) functional class classification as assessed by the treating physician",{"measure":24,"description":11,"timeFrame":15},"Change from baseline in left atrial dimension (LAD) or left atrial volume index (LAVI) assessed by transthoracic echocardiography",{"measure":26,"description":11,"timeFrame":15},"Change from baseline in interventricular septal thickness (IVST) assessed by transthoracic echocardiography",{"measure":28,"description":11,"timeFrame":12},"Change from baseline in E\u002Fe' ratio assessed by transthoracic echocardiography",{"measure":30,"description":11,"timeFrame":31},"Prescribed mavacamten dose (mg)","Day 1 and months 1, 2, 3, 6, 9, 12 and 15",{"measure":33,"description":11,"timeFrame":34},"Prescribed mavacamten maintenance dose (mg) during follow-up","Up to 15 months",{"measure":36,"description":11,"timeFrame":34},"Number of participants reaching mavacamten maintenance dose",{"measure":38,"description":11,"timeFrame":39},"Number of participants whose prescribed mavacamten dose changed during the observation period","Day 1 and and up to 15 months",{"measure":41,"description":11,"timeFrame":42},"Time (days) from Index Date to achieving mavacamten maintenance dose","Day 1 and up to 15 months",{"measure":44,"description":11,"timeFrame":34},"Number of participants that discontinued mavacamten treatment",{"measure":46,"description":11,"timeFrame":42},"Time (days) from Index Date to mavacamten discontinuation",{"measure":48,"description":11,"timeFrame":42},"Duration of mavacamten treatment during follow-up",{"measure":50,"description":51,"timeFrame":52},"Prior hypertrophic cardiomyopathy (oHCM) medication drug class","Drug class of background oHCM medications, including beta-blockers and calcium channel blockers","Baseline and up to 15 months",{"measure":54,"description":55,"timeFrame":52},"Prior hypertrophic cardiomyopathy (oHCM) medication dose","Dose of background oHCM medications, including beta-blockers and calcium channel blockers",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":57,"timePerspective":58,"maskingInfo":11},"COHORT","RETROSPECTIVE","The study will include adults in China diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiated mavacamten treatment between 24 October 2024 and 31 March 2026.",[61,66,70,74,78],{"label":62,"type":11,"description":63,"interventionNames":64},"Category A1. Sustained Monotherapy","Participants who initiate mavacamten as monotherapy and remained on monotherapy throughout follow-up.",[65],"Drug: Mavacamten",{"label":67,"type":11,"description":68,"interventionNames":69},"Category A2. Treatment Intensification","Participants who initiate mavacamten monotherapy and subsequently added one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications during follow-up.",[65],{"label":71,"type":11,"description":72,"interventionNames":73},"Category B1. Stable Combination Therapy at Initiation","Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and remain on combination therapy throughout follow-up.",[65],{"label":75,"type":11,"description":76,"interventionNames":77},"Category B2. Treatment Simplification","Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and subsequently discontinued all background oHCM medications, resulting in mavacamten monotherapy.",[65],{"label":79,"type":11,"description":80,"interventionNames":81},"Category C. Complex\u002FUnclassifiable","Participants whose treatment records indicate multiple treatment changes that could not be classified into the predefined treatment strategy groups.",[65],[83],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":11},"DRUG","Mavacamten","As per product label",[62,67,71,75,79],[89],{"name":5,"affiliation":5,"role":90},"STUDY_DIRECTOR",[92,97],{"name":93,"role":94,"phone":95,"phoneExt":11,"email":96},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":98,"role":94,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[100],{"facility":101,"status":11,"city":102,"state":11,"zip":11,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":11},"Fudan University Zhongshan Hospital","Shanghai","China","CN",{"type":106,"coordinates":107},"Point",[108,109],121.45806,31.22222,{"lat":109,"lon":108},{"type":112,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658060","evaluation-of-mavacamten-based-practice-in-chinese-adults-with-obstructive-hypertrophic-cardiomyopathy-100658060",false,"NCT07846059","Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy","Real-world Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy","REMAP-HCM","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be included:\n\n1. Diagnosis: Have a documented diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), identified by the corresponding International Classification of Diseases (ICD)-10 codes in the medical record system.\n2. Medication Exposure: Have a first-ever recorded prescription for Mavacamten within the Patient Identification Period (24 October 2024 to 31 March 2026). This date is defined as the Index Date.\n3. Age: Be ≥ 18 years of age at the Index Date.\n4. Treatment Continuity: Have at least two valid clinical records of any type (e.g., outpatient visit, inpatient encounter, prescription refill, laboratory test, or echocardiogram) after the Index Date.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.","ALL","18 Years",{"count":124,"type":125},800,"ESTIMATED","OBSERVATIONAL","The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background\u002Fconcomitant oHCM medications.",[129],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[131,85,132],"Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)","Hypertrophic cardiomyopathy","NOT_YET_RECRUITING","2026-09-23",{"date":136,"type":137},"2026-09-29","ACTUAL",{"date":139,"type":125},"2026-09-30",{"date":141,"type":125},"2027-04-30",{"name":5,"class":6},1]